Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1961 2
1962 2
1964 2
1965 2
1966 6
1967 5
1968 6
1969 3
1970 10
1971 2
1972 10
1973 2
1974 4
1975 8
1976 11
1977 15
1978 17
1979 15
1980 17
1981 17
1982 22
1983 29
1984 33
1985 53
1986 49
1987 67
1988 60
1989 65
1990 59
1991 63
1992 60
1993 65
1994 55
1995 73
1996 76
1997 72
1998 87
1999 104
2000 94
2001 93
2002 102
2003 131
2004 115
2005 155
2006 158
2007 165
2008 179
2009 183
2010 219
2011 263
2012 270
2013 329
2014 320
2015 301
2016 286
2017 278
2018 241
2019 263
2020 304
2021 353
2022 361
2023 84
Text availability
Article attribute
Article type
Publication date

Search Results

5,848 results
Results by year
Filters applied: . Clear all
Page 1
Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts.
Paluch AE, Bajpai S, Bassett DR, Carnethon MR, Ekelund U, Evenson KR, Galuska DA, Jefferis BJ, Kraus WE, Lee IM, Matthews CE, Omura JD, Patel AV, Pieper CF, Rees-Punia E, Dallmeier D, Klenk J, Whincup PH, Dooley EE, Pettee Gabriel K, Palta P, Pompeii LA, Chernofsky A, Larson MG, Vasan RS, Spartano N, Ballin M, Nordström P, Nordström A, Anderssen SA, Hansen BH, Cochrane JA, Dwyer T, Wang J, Ferrucci L, Liu F, Schrack J, Urbanek J, Saint-Maurice PF, Yamamoto N, Yoshitake Y, Newton RL Jr, Yang S, Shiroma EJ, Fulton JE; Steps for Health Collaborative. Paluch AE, et al. Among authors: yamamoto n. Lancet Public Health. 2022 Mar;7(3):e219-e228. doi: 10.1016/S2468-2667(21)00302-9. Lancet Public Health. 2022. PMID: 35247352 Free PMC article.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: yamamoto n. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Sugawara S, Lee JS, Kang JH, Kim HR, Inui N, Hida T, Lee KH, Yoshida T, Tanaka H, Yang CT, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Namba Y, Sumiyoshi N, Nakagawa K. Sugawara S, et al. Among authors: yamamoto n. Ann Oncol. 2021 Sep;32(9):1137-1147. doi: 10.1016/j.annonc.2021.06.004. Epub 2021 Jun 15. Ann Oncol. 2021. PMID: 34139272 Free article. Clinical Trial.
Safety monitoring of COVID-19 vaccines in Japan.
Yamaguchi T, Iwagami M, Ishiguro C, Fujii D, Yamamoto N, Narisawa M, Tsuboi T, Umeda H, Kinoshita N, Iguchi T, Noda T, Tsuruta S, Oka A, Morio T, Nakai K, Hayashi S. Yamaguchi T, et al. Among authors: yamamoto n. Lancet Reg Health West Pac. 2022 Mar 29;23:100442. doi: 10.1016/j.lanwpc.2022.100442. eCollection 2022 Jun. Lancet Reg Health West Pac. 2022. PMID: 35359913 Free PMC article. Review.
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Shinno Y, et al. Among authors: yamamoto n. Clin Lung Cancer. 2022 Jul;23(5):386-392. doi: 10.1016/j.cllc.2022.03.005. Epub 2022 Apr 29. Clin Lung Cancer. 2022. PMID: 35618627
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: yamamoto n. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Seto T, Nosaki K, Shimokawa M, Toyozawa R, Sugawara S, Hayashi H, Murakami H, Kato T, Niho S, Saka H, Oki M, Yoshioka H, Okamoto I, Daga H, Azuma K, Tanaka H, Nishino K, Tohnai R, Yamamoto N, Nakagawa K. Seto T, et al. Among authors: yamamoto n. J Immunother Cancer. 2022 Feb;10(2):e004025. doi: 10.1136/jitc-2021-004025. J Immunother Cancer. 2022. PMID: 35105689 Free PMC article. Clinical Trial.
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K. Sakata S, et al. Among authors: yamamoto n. Cancer Sci. 2022 Jan;113(1):221-228. doi: 10.1111/cas.15176. Epub 2021 Nov 7. Cancer Sci. 2022. PMID: 34704312 Free PMC article.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: yamamoto n. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Nakagawa K, Nadal E, Garon EB, Nishio M, Seto T, Yamamoto N, Park K, Shih JY, Paz-Ares L, Frimodt-Moller B, Zimmermann AH, Wijayawardana S, Visseren-Grul C, Reck M. Nakagawa K, et al. Among authors: yamamoto n. Clin Cancer Res. 2021 Oct 1;27(19):5258-5271. doi: 10.1158/1078-0432.CCR-21-0273. Clin Cancer Res. 2021. PMID: 34301751 Free PMC article. Clinical Trial.
5,848 results